tbuckley/cabot-search huggingface dataset:
Cytokine-Like 1 Is a Novel Proangiogenic Factor Secreted by and Mediating Functions of Endothelial Progenitor Cells
Authors: Doris Schneller, Renate Hofer-Warbinek, Caterina Sturtzel, Karoline Lipnik, Burcu Gencelli, Monika Seltenhammer, Mingjie Wen, Julia Testori, Martin Bilban, Andreas Borowski, Markus Windwarder, Stephanie S. Kapel, Eva Besemfelder, Petra Cejka, Andreas Habertheuer, Bernhard Schlechta, Otto Majdic, Friedrich Altmann, Alfred Kocher, Hellmut G. Augustin, Werner Luttmann, Erhard Hofer
Journal: Circulation Research (2019)

Endothelial colony forming cells (ECFCs) or late blood outgrowth endothelial cells can be isolated from human cord or peripheral blood, display properties of endothelial progenitors, home into ischemic tissues and support neovascularization in ischemic disease models.To assess the functions of CYTL1 (cytokine-like 1), a factor we found preferentially produced by ECFCs, in regard of vessel formation.We show by transcriptomic analysis that ECFCs are distinguished from endothelial cells of the vessel wall by production of high amounts of CYTL1. Modulation of expression demonstrates that the factor confers increased angiogenic sprouting capabilities to ECFCs and can also trigger sprouting of mature endothelial cells. The data further display that CYTL1 can be induced by hypoxia and that it functions largely independent of VEGF-A (vascular endothelial growth factor-A). By recombinant production of CYTL1 we confirm that the peptide is indeed a strong proangiogenic factor and induces sprouting in cellular assays and functional vessel formation in animal models comparable to VEGF-A. Mass spectroscopy corroborates that CYTL1 is specifically O-glycosylated on 2 neighboring threonines in the C-terminal part and this modification is important for its proangiogenic bioactivity. Further analyses show that the factor does not upregulate proinflammatory genes and strongly induces several metallothionein genes encoding anti-inflammatory and antiapoptotic proteins.We conclude that CYTL1 can mediate proangiogenic functions ascribed to endothelial progenitors such as ECFCs in vivo and may be a candidate to support vessel formation and tissue regeneration in ischemic pathologies.
Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04)
Authors: A.G.J. van Rossum, M. Hoogstraat, M. Opdam, H. Horlings, L. Wessels, R.M. Kerkhoven, A.E. van Leeuwen - Stok, H.M. Oosterkamp, M. Kok, S.C. Linn
Journal: Annals of Oncology (2018)
Evidence-based physiotherapy needs evidence-based marketing
Authors: Joshua Robert Zadro, Mary O’Keeffe, Christopher G Maher
Journal: British Journal of Sports Medicine (2018)

Just over 20 years ago, an editorial titled ‘Now is the time for evidence based physiotherapy’ highlighted the need for high-quality research on the effectiveness of physiotherapy treatments.1 Today, we arguably have sufficient evidence to allow physiotherapists to choose an evidence-based approach to clinical practice. For example, the Physiotherapy Evidence Database (PEDro) indexes nearly 40 000 randomised controlled trials, systematic reviews and clinical practice guidelines. More recently, physiotherapy associations have dramatically increased the marketing of physiotherapy services. This reflects a rapidly expanding workforce and more jurisdictions allowing the public to directly access physiotherapy without the need for medical referral.

Marketing of physiotherapy sometimes draws on evidence but at other times makes claims for physiotherapist roles and services that are not supported by evidence. This could mislead the public and could draw attention away from the strong evidence base within physiotherapy. Consider these examples of marketing from the websites of physiotherapy associations and leading physiotherapy journals from the USA, Australia and UK.

Recent marketing that early physical therapy could help …
Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: A retrospective cohort study
Authors: M. Freeman, K. Gupte-Singh, M. You, T.K. Le, C. Ritchings, S. Rao, S. Jang
Journal: Annals of Oncology (2018)
P2.01-101 Dynamic Monitoring of Gene Alterations with ctDNA by NGS for EGFR Mutated Lung Adenocarcinoma Treated with Gefitinib in BENEFIT Study (CTONG 1405)
Authors: J. Duan, S. Wang, Z. Wang, H. Bai, J. Zhao, H. Gao, Y. Cheng, J. Wang
Journal: Journal of Thoracic Oncology (2018)
Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)
Authors: T. Decaens, C. Barone, E. Assenat, M. Wermke, A. Fasolo, P. Merle, J.F. Blanc, V. Grando, R. Bruns, J. Straub, C. Zhao, S. Faivre
Journal: Annals of Oncology (2018)
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients
Authors: G. Pelizzari, L. Gerratana, D. Basile, S. Zago, M.G. Vitale, M. Bartoletti, C. Lisanti, V. Fanotto, C. Corvaja, L. Bortot, A. Liguori, M. Cinausero, S. Russo, C. Andreetta, M. Bonotto, M. Mansutti, A.M. Minisini, F. Curcio, G. Fasola, F. Puglisi
Journal: Annals of Oncology (2018)
P2.13-28 Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC
Authors: C. Steendam, R. Van Schaik, E. Oomen - De Hoop, P. Atmodimedjo, E. De Jonge, J. Von Der Thüsen, W. Dinjens, E.J. Dubbink, J. Aerts
Journal: Journal of Thoracic Oncology (2018)
Adjuvant radiation therapy leads to an up-regulation of programmed death ligand 1 (PD-L1) on circulating epithelial tumor cells (CETCs) which might contribute to radioresistance in primary breast cancer patients
Authors: D. Schott, M. Pizon, U. Pachmann, K. Pachmann, M. Mäurer
Journal: Annals of Oncology (2018)
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)
Authors: B.C.M. Hermans, J.L. Derks, E. Thunissen, R.J. van Suylen, M.A. den Bakker, H.J.M. Groen, E.F. Smit, R.A. Damhuis, E.C. van den Broek, P. PALGA-group, C.M. Stallinga, G.M. Roemen, E.J. Speel, A.-M.C. Dingemans
Journal: Annals of Oncology (2018)
Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150
Authors: M.P. Ducreux, A.-L. Cheng, S. Qin, A.X. Zhu, M. Ikeda, T.-Y. Kim, D.-Z. Xu, W. Verret, J. Liu, R.S. Finn, P.R. Galle
Journal: Annals of Oncology (2018)
P3.03-07 Co-Occurring Genomic Alterations in EGFR Altered Chinese Lung Adenocarcinoma Patients
Authors: M. Wang, H. Zhong, L. Dai, L. Wang, P. Shen, Y. Wang, D. Jiang, M. Zheng, D. Wu, F. Shi, K. Wang, C. Li, H. Chen, Y. Dong, W. Shi, K. Wang, M. Yao
Journal: Journal of Thoracic Oncology (2018)
Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study
Authors: M. Thomas, S. Ponce Aix, A. Navarro Mendivil, J. Riera Knorrenschild, M. Schmidt, E. Wiegert, K. Kapp, C. Mauri, M. Domine Gomez, J. Kollmeier, P. Sadjadian, K.-P. Fröhling, R.M. Huber, M. Wolf
Journal: Annals of Oncology (2018)
P2.12-05 SUKSES (Small Cell Lung Cancer Umbrella Korea Studies): A Phase II Biomarker-Driven Umbrella Study in Relapsed or Refractory SCLC
Authors: S. Park, J.Y. Hur, S.E. Yoon, K. Lee, Y. Kim, J.H. Cho, J. Sun, S. Lee, J.S. Ahn, M. Ahn, K. Park
Journal: Journal of Thoracic Oncology (2018)
Changes in CpG methylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A in gastric adenocarcinoma
Authors: N.N. Timoshkina, O.I. Kit, D.I. Vodolazhskiy, N.V. Soldatkina, Y.A. Gevorkyan, N.S. Samoylenko, D.A. Kharagezov, M.N. Duritskiy, A.V. Dashkov, D.O. Kaymakchi, D.S. Petrov, S.A. Ilchenko, V.A. Sustretov, L.Y. Vladimirova
Journal: Annals of Oncology (2018)
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer
Authors: David D. Yang, Brandon A. Mahal, Vinayak Muralidhar, Neil E. Martin, Peter F. Orio, Kent W. Mouw, Martin T. King, Toni K. Choueiri, Quoc-Dien Trinh, Karen E. Hoffman, Daniel E. Spratt, Felix Y. Feng, Paul L. Nguyen
Journal: European Urology (2018)
Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
Authors: H. Shirasu, T. Yokota, K. Fushiki, H. Inoue, M. Shibata, M. Furuta, T. Kawakami, S. Kawai, S. Hamauchi, A. Todaka, T. Tsushima, N. Machida, K. Yamazaki, A. Fukutomi, Y. Onozawa, H. Yasui
Journal: Annals of Oncology (2018)
Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study
Authors: B. De Craene, J. Van de Velde, E. Bellon, M. Gazin, E. Rondelez, L. Vandenbroeck, T. Vanhoey, N. Elsen, L.C. Melchior, G.L. Willemoe, E. Watkin, N. Arens, C. Altmann, K. Decanniere, E. Sablon, G.G. Maertens
Journal: Annals of Oncology (2018)
Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)
Authors: E.J. Small, D. Cella, K. McQuarrie, F. Saad, B.A. Hadaschik, J.N. Graff, H. Uemura, S. Oudard, M.K. Yu, S. Hudgens, A. Lopez-Gitlitz, B. Rooney, M. Morris, M.R. Smith
Journal: Annals of Oncology (2018)
P1.16-50 The Role of Adjuvant Therapy for Patients with Early Stage Large Cell Neuroendocrine Lung Cancer: A National Analysis
Authors: V. Raman, C. Yang, O. Jawitz, C. Erkmen, B. Tong, T. D'Amico, M. Berry, D. Harpole
Journal: Journal of Thoracic Oncology (2018)
Abstract 16009: Y RNA Fragments Enriched in Exosomes From Cardiosphere-derived Cells Mediate Cardioprotection and Macrophage Polarization
Authors: Linda Cambier, Geoffrey de Couto, Ahmed Ibrahim, Eduardo Marbán
Journal: Circulation (2015)

Background: Exosomes secreted by cardiosphere-derived cells (CDCs) are critical agents of regeneration and cardioprotection following ischemic injury, mediating the beneficial therapeutic effects of CDCs. Transfer of exosomal RNA to target cells is important for bioactivity. Objective: We sought to determine the RNA content of CDCs-secreted exosomes (CDC-exo), and to assess the contributions of selected small non-coding RNAs to the therapeutic efficacy of CDC-exo. Methods: Using next-generation sequencing (Illumina), we characterized the RNA content of CDC-exo. By direct transfection of fluorescently-labelled oligoribonucleotides, we delivered and tracked selected RNA fragments that are highly enriched in CDC-exo. In order to examine potential cytoprotective effects, neonatal rat ventricular myocytes (NRVMs) were pretreated with each of these fragments or a scrambled control fragment prior to H2O2-induced oxidative stress. Effects on gene expression were assessed by transfection of the fragments into bone marrow-derived macrophages. Results: Several noncoding RNA species were present in CDC-exo. Among these, Y RNAs (either whole or in fragments of the 5’ end) constituted 18% of all hits. From this data set, we selected two highly-enriched Y RNA fragments. Both fragments localized to the cytoplasm of CDC, NRVM and macrophages, and conferred augmented resistance to oxidative stress of NRVM (64.25±31.13% viability vs. 44±26.85%; p=0.06). Additionally, macrophages transfected with Y fragments exhibit rapid, robust polarization to a distinctive gene expression profile notable for upregulation of IL-10 (83.07 vs. 0.59 fold; p&lt;0.0001), an anti-inflammatory cytokine. Conclusions: Here, we demonstrated that abundant noncoding RNA components of CDC-exo, Y RNA fragments, are bioactive components of CDC-exo. Two distinct fragments confer cardioprotection and also induce a strong anti-inflammatory response in macrophages. Although several components of the CDC-exo payload (including miRNA) contribute to functional efficacy, the present findings demonstrate the capacity of Y RNA fragments, an RNA species of previously-unknown function, to elicit therapeutic effects in vitro.
GEMOX plus hypofractionated radiotherapy for unresectable locally advanced pancreatic cancer: Results from a phase II study
Authors: A. Passardi, E. Scarpi, E. Neri, E. Parisi, G. Ghigi, G. Ercolani, A. Gardini, G. La Barba, F. Pagan, A. Casadei Gardini, L.G. Frassineti, F. Ferroni, M. Valgiusti, S.A.M.Z.M. Darwish, A. Romeo
Journal: Annals of Oncology (2018)
Benefit of adjuvant systemic therapies in HR+ HER2- pT1ab node-negative breast carcinomas
Authors: A. De Nonneville, A. Gonçalves, J.-M. Boher, J.-M. Classe, M. Cohen, P.-E. Colombo, F. Reyal, M.-P. Chauvet, E. Jouve, E. Darai, G. Blache, C. Coutant, P. Gimbergues, C. Mazouni, R. Rouzier, R. Villet, P. Crochet, A.-S. Azuar, E. Lambaudie, G. Houvenaeghel
Journal: Annals of Oncology (2018)
OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis
Authors: A. Desai, T. Karrison, B. Rose, Y. Tan, B. Hill, E. Pemberton, C. Straus, T. Seiwert, H.L. Kindler
Journal: Journal of Thoracic Oncology (2018)
Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials
Authors: V.K. Lam, D.S. Hong, J.V. Heymach, G. Blumenschein, M.O. Butler, M. Johnson, B. Creelan, J.F. Gainor, R. Govindan, R. Mudad, J. Neal, F. Brophy, F. Fang, N. Hyland, T. Holdich, Y. Ma, T. Trivedi, E. Norry, R.G. Amado
Journal: Annals of Oncology (2018)
P1.14-30 Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection
Authors: H. Yamamoto, K. Namba, H. Yamamoto, J. Soh, K. Shien, T. Kurosaki, S. Ohtani, M. Okazaki, S. Sugimoto, M. Yamane, T. Oto, S. Toyooka
Journal: Journal of Thoracic Oncology (2018)
Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO)
Authors: S. Pusceddu, C. Vernieri, M. Di Maio, N. Prinzi, M. Torchio, R. Buzzoni, X.-M. Truong-Thanh, V. Mazzaferro, F.G.M. de Braud
Journal: Annals of Oncology (2018)
Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)
Authors: K. Xu, A. Lo, V. Chin, C. Gzell, C. O’Connor, D. Forstner, R. Gallagher, R. Bova, J. Crawford, R. Harvey, A. Lochhead, P. Earls, M.R. Qiu, E. Hsu, G. Bigg-Wither, L. Chan, H. Bao, P. Foltyn, H.-W. Sim, A. Prawira
Journal: Annals of Oncology (2018)
Abstract 13343: Green Tea Polyphenol Attenuates Experimental Abdominal Aortic Aneurysm Progression in a Rat Model
Authors: Shuji Setozaki, Kenji Minakata, Shingo Hirao, Tadashi Ikeda, Ryuzo Sakata
Journal: Circulation (2015)

Introduction: Destruction of elastin in the media layer is thought to play an important role in the development of abdominal aortic aneurysm (AAA). It has been reported that a major component of green tea, epigallocatechin-3-gallate (EGCG), enhances the stabilization of elastin and facilitates the regeneration of elastin in vitro. However, it is unknown whether EGCG attenuates AAA development in vivo. Hypothesis: We aimed to prove the hypothesis that administration of EGCG can attenuate AAA development. Methods: We divided 48 male SD rats into two groups: the control group (n=24) and the EGCG group (n=24). A 1.0 mmol/L EGCG solution was administered orally for 2 weeks prior to the induction of AAAs in the EGCG group until sacrifice, while tap water was given to the control group. AAAs were induced by administration of intraluminal elastase and extraluminal calcium chloride. Immediately before the induction of the AAAs (on day 0) and on day 7 after their induction, 6 rats were sacrificed in each group. In addition, 12 rats were sacrificed in each group on day 28. The aortic size was measured and aortic tissues underwent biochemical and histological evaluation. Results: The abdominal aortic size on day 28 was significantly smaller in the EGCG group than in the control group (2.34 ± 0.12 vs 2.86 ± 0.19mm, p&lt;.0001). The thickness of the media layer increased significantly in the EGCG group compared with that of the control group (68.4 ± 13.6 vs 46.9 ± 13.6μm, p&lt;0.001). The elastin content of the media layer was significantly greater in the EGCG group than in the control group (20.3 ± 4.8 vs 9.6 ± 3.7%, p&lt;.0001). The lysyl oxidase (LOX) mRNA level in the aortic tissues on day 0 was significantly higher in the EGCG group than in the control group (p&lt;0.05). Transmission electron microscopy images showed the growth of new elastic fibers in the EGCG group. On immunohistochemical staining, the LOX-positive area was significantly larger in the EGCG group than in the control group (p&lt;0.01). Conclusions: Oral treatment with EGCG attenuated AAA progression in a rat model via organization and stabilization of elastin in the media layer by increasing LOX production. Thus, the green tea polyphenol EGCG has the potential to serve as a pharmacological agent to treat and prevent AAAs.
Real world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset
Authors: J.H. Kang, B.C. Cho, D.-W. Kim, K. Park, J.-S. Lee, S.S. Yoo, S.Y. Lee, C.H. Kim, S.H. Jang, Y.-C. Kim, H.-K. Yoon, S.-W. Kim
Journal: Annals of Oncology (2018)
EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis
Authors: A. Gonçalves, W. Eiermann, H.S. Rugo, J. Ettl, S.A. Hurvitz, R. Yerushalmi, M. Martín, M. Al-Adhami, I.C. Tudor, J.L. Blum, A.L. Hannah, J.K. Litton
Journal: Annals of Oncology (2018)
MA06.10 Germline Mutation in ATM Affect Lung Cancer Risk with High Effect
Authors: X. Ji, D. Zhu, C. Pikielny, O. Gorlova, M. Landi, J. Field, P. Brennan, M. Johansson, R. Hung, J. Mckay, C. Amos
Journal: Journal of Thoracic Oncology (2018)
Abstract 15321: Increased Expression of Mircorna-21 Contributes to Reduced Microvascular Function in Young Adult Regular Binge Drinkers
Authors: Jing-Tan Bian, Abeer M Mahmoud, Kumar U Kotlo, Mariann R Piano, Shane A Phillips
Journal: Circulation (2016)

Departments of Medicine1, Biobehavioral Health Science2, Physical Therapy3, Kinesiology and Nutrition4, The University of Illinois at Chicago Binge drinking (BD) is one of the biggest health danger...
P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study
Authors: N. Peled, O. Rotem, A. Rozenblum, H. Nechushtan, L. Chen, E. Dudnik, A. Zer, S. Yust-Katz, I. Shelef, L. Roisman, E. Inbar
Journal: Journal of Thoracic Oncology (2018)
P2.06-30 Association of Histopathological Patterns of Mesothelioma and Response to Treatment with Chemotherapy
Authors: J. Rodriguez-Cid, D. Bonilla-Molina, E.S. Peña Mirabal, J.A. Alatorre Alexander, L. Martínez Barrera, J.P. Díaz Rico, P. Santillan Doherty
Journal: Journal of Thoracic Oncology (2018)
Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome
Authors: S. Cedres Perez, M. Sanso, A. Hernando-Calvo, A. Callejo, N. Pardo Aranda, A. Navarro Mendivil, A. Martinez, J. Remon, J.M. Miquel, G. Rodriguez, V. Monton, G. Villacampa, R. Dienstmann, A. Vivancos, E. Felip Font
Journal: Annals of Oncology (2018)
Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study
Authors: M. Oliva Bernal, S. Lien, B.X. Wang, S.C. Yang, A. Spreafico, R. Jang, S. Elston, S. Jennings, H. Jiang, B. Haibe-Kains, T. Pugh, P. Ohashi, L.L. Siu, A. Hansen
Journal: Annals of Oncology (2018)
Soluble immune biomarkers to anti-PD1 treatment in non-small cell lung cancer (NSCLC)
Authors: J. Garde-Noguera, E. Jantus-Lewintre, B. Honrubia Peris, S. Gallach Garcia, F. Zhang, J. García Sánchez, S. Calabuig Fariñas, A. Blasco Cordellat, N. Piera Molons, J. Vidal-Martinez, J. Murado-Pardo, L.D. Condori Farfan, R. Gisbert-Criado, E. Escorihuela, C. Camps
Journal: Annals of Oncology (2018)
Prognostics factors in adenoid cystic carcinoma of the head and neck (ACCHN): Retrospective study of 15 years
Authors: P. Neji, R.S. Conde, S. Esteves, M.T.A. Alexandre, M. Ferreira, E. Netto, J. Santos, M. Magalhães, A. Moreira
Journal: Annals of Oncology (2018)
Molecular Pathogenesis of the Tauopathies
Authors: Jürgen Götz, Glenda Halliday, Rebecca M. Nisbet
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

The tauopathies constitute a group of diseases that have Tau inclusions in neurons or glia as their common denominator. In this review, we describe the biochemical and histological differences in Tau pathology that are characteristic of the spectrum of frontotemporal lobar degeneration as primary tauopathies and of Alzheimer's disease as a secondary tauopathy, as well as the commonalities and differences between the familial and sporadic forms. Furthermore, we discuss selected advances in transgenic animal models in delineating the different pathomechanisms of Tau.
Individual and familial phenotype in hereditary ovarian cancer
Authors: M.B.D.O. Mira, I. Miguel, S. Fragoso, A. Opinião, A.C. Luís, A. Clara, S. Bento, P. Machado, S. Santos, P. Rodrigues, J. Parreira, F. Vaz
Journal: Annals of Oncology (2018)
Effects of fine particulate matter and its constituents on childhood pneumonia: a cross-sectional study in six Chinese cities
Authors: Wenming Shi, Cong Liu, Dan Norback, Qihong Deng, Chen Huang, Hua Qian, Xin Zhang, Jan Sundell, Yinping Zhang, Baizhan Li, Haidong Kan, Zhuohui Zhao
Journal: The Lancet (2018)
SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC)
Authors: G.G. Steger, F. Puglisi, C. Timcheva, L. Costa, M. Casa-Nova, D. Hitzl, B. Dampier, N. Lindegger
Journal: Annals of Oncology (2018)
Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics
Authors: D. Ahn, A. Barzi, R.A. Miksad, A. Surinach, F.A. Corvino, A. Valderrama, K. Mamlouk, S. Pulgar, T. Bekaii-Saab
Journal: Annals of Oncology (2018)
Predictive factors of outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
Authors: Y. Suzuki, M. Kan, G. Kimura, K. Umemoto, K. Watanabe, M. Sasaki, H. Takahashi, Y. Hashimoto, H. Imaoka, I. Ohno, S. Mitsunaga, M. Ikeda
Journal: Annals of Oncology (2018)
Benefits May Persist After Antihypertensive and Statin Treatment
Authors: Anita Slomski
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal